A leveraged CRO spin-off turnaround: Fortrea’s backlog and secular outsourcing tailwinds are intact, but the stock’s fate hinges on margin recovery and deleveraging.
Overview
Fortrea Holdings (FTRE) is a global Contract Research Organization created via a June 2023 spin from Labcorp, effectively re-establishing the historical Covance CRO franchise as an independent company. It employs ~19,000 clinical professionals across 100+ countries and supports biopharma, biotech, medical device, and diagnostics customers by executing and optimizing clinical trials from Phase I through Phase IV. The operating model is split into Clinical Pharmacology (early-phase, precision-intensive work such as first-in-human studies, radiolabeled absorption, and drug-drug interaction trials) and Clinical Development (late-stage trials and post-approval surveillance at global scale). Commercially, Fortrea serves sponsors via Full-Service Outsourcing (end-to-end trial accountability) and a Functional Service Provider model (outsourcing specific functions like biostatistics, pharmacovigilance, or medical writing while sponsors retain governance). Revenue is concentrated in high-capital clients: ~57% of YTD Q3 2025 revenue from Large Pharma, but the top ten customers represent ~60% of total revenue, creating dependence on a small set of R&D budgets. Therapeutically, Fortrea is strongest in complex, high-growth areas (oncology leading, plus immunology, neurology, rare disease, and cell/gene therapy). The company is pursuing analytics- and AI-enabled execution through its Xcellerate platform and consulting capabilities. Despite a difficult post-spin transition, Fortrea’s multi-year visibility is supported by a **$7.644B backlog (Q3 2025)**, anchoring the turnaround narrative around stabilizing operations, improving margins, and converting backlog into higher-quality earnings.